Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer
Improvements in PFS were also seen among patients with brain metastases.
Source: pharmacytimes.com
Sara Hurvitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sara Hurvitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sara Hurvitz Today - Breaking & Trending Today
Dr Sara Hurvitz: Addition of Tucatinib to T-DM1 Improves Outcomes in HER2+ Metastatic Breast Cancer
Sara Hurvitz, MD, FACP, shares insights into the results of the HER2CLIMB-02 trial, which saw patients with HER2-positive breast cancer benefit from the addition of tucatinib to trastuzumab emtansine (T-DM1).
Source: ajmc.com
Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer
Adding agent to T-DM1 resulted in 2-month progression-free survival improvement
Source: medpagetoday.com
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 --...
Source: marketscreener.com
The Future of HER2+ Breast Cancer Treatment
Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.
Source: onclive.com